Syndax Pharmaceuticals Inc header image

Syndax Pharmaceuticals Inc

SNDX

Equity

ISIN null / Valor 24112479

NASDAQ (2026-11-06)
USD 9.54+1.81%

Syndax Pharmaceuticals Inc
UMushroom community rating:

star star star star star
4.28 18 votes No rating yet
NegativeNeutralPositive

About company

Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer treatment. The company aims to extend and improve the lives of cancer patients by leveraging cutting-edge scientific research and advancements. Syndax collaborates with various stakeholders in the medical and scientific communities to identify and develop promising drug candidates. The company's pipeline includes treatments designed to address unmet medical needs in oncology, with a particular emphasis on novel mechanisms of action and overlooked aspects of cancer biology. Through these efforts, Syndax seeks to bring new, effective treatment options to market, enhancing patient outcomes and advancing the field of cancer therapy.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-35.1%1Y
-33.8%3Y
-45.8%5Y

Performance

53.0%1Y
58.3%3Y
56.1%5Y

Volatility

Market cap

852 M

Market cap (USD)

Daily traded volume (Shares)

4,171,072

Daily traded volume (Shares)

1 day high/low

12.75 / 12.4

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.28

18 votes
Performance:
starstarstarstarstar
3.94
Innovation:
starstarstarstarstar
4.33
Society:
starstarstarstarstar
4.44
Nature:
starstarstarstarstar
4.17
Liam Hawkeswood
Switzerland, 18 Nov 2025
star star star star star
Liam Hawkeswood
Switzerland, 11 Nov 2025
star star star star star
****** Panggabean
UK, 09 Nov 2025
star star star star star
High risk and volatile performance. However, it has high upside potential and people are anticipating future returns

EQUITIES OF THE SAME SECTOR

Lupin Limited
Lupin Limited Lupin Limited Valor: 11598960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.13%INR 1,990.00
ImmunityBio Inc
ImmunityBio Inc ImmunityBio Inc Valor: 110468647
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
7.80%USD 8.63
Astrana Health Inc
Astrana Health Inc Astrana Health Inc Valor: 28041888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-11.56%USD 34.50
2invest AG
2invest AG 2invest AG Valor: 110098281
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.25%EUR 6.32
Terveystalo Oyj
Terveystalo Oyj Terveystalo Oyj Valor: 37893402
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.81%EUR 6.23
Siemens Healthineers AG
Siemens Healthineers AG Siemens Healthineers AG Valor: 40652181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.76%EUR 44.66
Beiersdorf AG
Beiersdorf AG Beiersdorf AG Valor: 324660
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.70%EUR 85.26
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.03%USD 74.29
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA Valor: 332902
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.18%EUR 52.48
Allogene Therapeutics Inc
Allogene Therapeutics Inc Allogene Therapeutics Inc Valor: 43756548
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.59%USD 1.04